UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study
Key facts
- Who runs it
- Changhai Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,109 people enrolled
- Started
- 8 Jun 2023
- Ended
- 1 Jul 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- urine sample collection
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants aged ≥ 18 years and signed informed consent form
- Participants presented with hematuria (≥ 3 RBCs/HPF) and meet one of the following criteria:; Patients recommended to undergo cystoscopy or ureteroscopy; Patients with treatment-naïve, pathology-confirmed urothelial carcinoma; Patients diagnosed with benign genitourinary disease
- Participants diagnosed with cancer other than urothelial carcinoma
Who cannot take part
- Participants with history of urothelial carcinoma
- Participants with urothelial carcinoma accompanied by other malignancy
- Individuals unwilling to sign the consent form or unwilling to provide urine sample for test or quality of urine sample is poor
- Patients unsuitable for this clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hematuria is recognized as an important sigh of potential urinary tract malignancy. Therefore, understanding the disease processes and discovering the potential urothelial carcinoma (UC) underlying this important sign is critical. Cystoscopy, urine cytology and imaging are most reliable methods for UC diagnosis, but certain drawbacks exist for these methods, such as invasiveness or inaccuracy. Chromosomal instability (CIN) is a hallmark of human cancer, and it's related with tumor stage and grade. Previous research has proved that analyzing CIN of the DNA extracted from urothelial cells in urine samples seems a promising method for detecting UC. Here the investigators intend to assess CIN's performance for hematuria evaluation.
The 2 groups in the trial
- Hematuria patients
Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria.
Treatment: urine sample collection
- Non-hematuria patients
Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer.
Treatment: urine sample collection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Hematuria Evaluation by Whole-genome Sequencing of Urine-Exfoliated Cell DNA, A Prospective, Multi-center Study
- Record updated
- 12 November 2026